AbbVie 2014 Annual Report Download - page 5

AbbVie Inc.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 10-K
(MARK ONE)
嘺ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
OR
䡺TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2014
Commission file number 001-35565
Delaware 32-0375147
(State or other jurisdiction of (I.R.S. employer
incorporation or organization) identification number)
1 North Waukegan Road
North Chicago, Illinois 60064-6400 [phone]
(Address of principal executive offices) (telephone number)
Securities Registered Pursuant to Section 12(b) of the Act:
Title of Each Class Name of Each Exchange on Which Registered
Common Stock, par value $0.01 per share New York Stock Exchange
Chicago Stock Exchange
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes 嘺No 䡺
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.
Yes 䡺No 嘺
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes 嘺No 䡺
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any,
every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding
12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes 嘺No 䡺
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this
chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. 䡺
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or
a smaller reporting company. See the definitions of ‘‘large accelerated filer,’’ ‘‘accelerated filer’’ and ‘‘smaller reporting
company’’ in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer 嘺Accelerated Filer 䡺Non-accelerated Filer 䡺Smaller Reporting Company 䡺
(Do not check if a
smaller reporting company)
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).
Yes 䡺No 嘺
The aggregate market value of the 1,574,311,912 shares of voting stock held by non-affiliates of the registrant,
computed by reference to the closing price as reported on the New York Stock Exchange, as of the last business day of
AbbVie Inc.’s most recently completed second fiscal quarter (June 30, 2014), was $88,854,164,315. AbbVie has no non-voting
common equity.
Number of common shares outstanding as of January 31, 2015: 1,593,886,909
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the 2015 AbbVie Inc. Proxy Statement are incorporated by reference into Part III. The Proxy Statement will
be filed on or about March 20, 2015.